Monotherapy studies of idelalisib in patients with NHL
| First author . | Phase . | Population . | n . | ORR (CR) . | Median DOR . |
|---|---|---|---|---|---|
| Flinn28 | 1 | Relapsed/refractory indolent B-cell NHL | 64 | 47 (2) | 18.4 mo |
| Kahl24 | 1 | Relapsed/refractory MCL | 39 | 40 (5) | 2.7 mo |
| Gopal19 | 2 | Relapsed/refractory indolent B-NHL | 125 | 57 (6) | 12.5 mo |
| First author . | Phase . | Population . | n . | ORR (CR) . | Median DOR . |
|---|---|---|---|---|---|
| Flinn28 | 1 | Relapsed/refractory indolent B-cell NHL | 64 | 47 (2) | 18.4 mo |
| Kahl24 | 1 | Relapsed/refractory MCL | 39 | 40 (5) | 2.7 mo |
| Gopal19 | 2 | Relapsed/refractory indolent B-NHL | 125 | 57 (6) | 12.5 mo |